Budesonide orodispersible tablets are superior to maintain combined clinical and histological remission in adult patients with eosinophilic esophagitis: Results from the 48-weeks, double-blind, placebo-controlled pivotal EOS-2 trial

(1) Swiss EoE Research Network,Olten,Switzerland

(2) Hospital General de Tomelloso Dept. of Digestive Health,Tomelloso,Spain

(3) Coopertion of Internal Medicine Center for Digestive Diseases,Hamburg,Germany

(4) Klinikum Bayreuth Abt. Pathology,Bayreuth,Germany

(5) Technische Universität München,München,Germany

(6) USZ Zürich,Zürich,Switzerland

(7) Hospital Universitario de La Princesa,Madrid,Spain

(8) Hospital 12 de Octubre,Madrid,Spain

(9) Sana Klinikum Lichtenberg,Berlin,Germany

(10) CRH Clinic Siloah,Hannover,Germany

(11) Universitätsspital Basel,Basel,Switzerland

(12) St. George`s University Hospitals,London,United Kingdom

(13) Otto-Von Guericke University,Madgeburg,Germany

(14) Academic Medical Center, AMC, Inflammatory Bowel Disease Centre,Amsterdam,Netherlands

(15) Praxis,Berlin,Germany

(16) Dr. Falk Pharma GmbH,Freiburg,Germany

(17) University Hospital (CHUV),Lausanne,Switzerland

(18) Durham University,North Tyneside,United Kingdom



This item was part of the What's hot in eosinophilic oesophagitis (Posters) session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019